Enhanced Exposure of Human Immunodeficiency Virus Type 1 Primary Isolate Neutralization Epitopes through Binding of CD4 Mimetic Compounds

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Journal of Virology

• Publication date

  2010-05-26

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1128/JVI.00227-10PMID 20504942PMCID PMC2897603
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• CD4 mimics targeting the mechanism of HIV entry.

  2010cited by this paper
• Human immunodeficiency virus type 1 evasion of a neutralizing anti-V3 antibody involves acquisition of a potential glycosylation site in V2.

  2010cited by this paper
• Soluble CD4 and CD4-Mimetic Compounds Inhibit HIV-1 Infection by Induction of a Short-Lived Activated State

  2009cited by this paper
• High titer HIV-1 V3-specific antibodies with broad reactivity but low neutralizing potency in acute infection and following vaccination.

  2009cited by this paper
• Altered sensitivity of an R5X4 HIV-1 strain 89.6 to coreceptor inhibitors by a single amino acid substitution in the V3 region of gp120.

  2008cited by this paper
• Autologous Neutralizing Humoral Immunity and Evolution of the Viral Envelope in the Course of Subtype B Human Immunodeficiency Virus Type 1 Infection

  2008cited by this paper
• Human Immunodeficiency Virus Type 2 (HIV-2)/HIV-1 Envelope Chimeras Detect High Titers of Broadly Reactive HIV-1 V3-Specific Antibodies in Human Plasma

  2008cited by this paper
• Small-molecule CD4 mimics interact with a highly conserved pocket on HIV-1 gp120.

  2008influential reference
• Impact of V2 Mutations on Escape from a Potent Neutralizing Anti-V3 Monoclonal Antibody during In Vitro Selection of a Primary Human Immunodeficiency Virus Type 1 Isolate

  2007cited by this paper
• HIV-1 subtype A envelope variants from early in infection have variable sensitivity to neutralization and to inhibitors of viral entry

  2007cited by this paper
• Resistance profile of a neutralizing anti-HIV monoclonal antibody, KD-247, that shows favourable synergism with anti-CCR5 inhibitors

  2006cited by this paper
• Sequential Immunization with V3 Peptides from Primary Human Immunodeficiency Virus Type 1 Produces Cross-Neutralizing Antibodies against Primary Isolates with a Matching Narrow-Neutralization Sequence Motif

  2006cited by this paper
• Thermodynamics of binding of a low-molecular-weight CD4 mimetic to HIV-1 gp120.

  2006cited by this paper
• Anti-V3 Humanized Antibody KD-247 Effectively Suppresses Ex Vivo Generation of Human Immunodeficiency Virus Type 1 and Affords Sterile Protection of Monkeys against a Heterologous Simian/Human Immunodeficiency Virus Infection

  2006cited by this paper
• Cryptic Nature of a Conserved, CD4-Inducible V3 Loop Neutralization Epitope in the Native Envelope Glycoprotein Oligomer of CCR5-Restricted, but Not CXCR4-Using, Primary Human Immunodeficiency Virus Type 1 Strains

  2005cited by this paper
• Antigenic conservation and immunogenicity of the HIV coreceptor binding site

  2005cited by this paper
• Isolation of TAK-779-resistant HIV-1 from an R5 HIV-1 GP120 V3 Loop Library*

  2005cited by this paper
• Antibody vs. HIV in a clash of evolutionary titans.

  2005cited by this paper
• Identification of N-phenyl-N'-(2,2,6,6-tetramethyl-piperidin-4-yl)-oxalamides as a new class of HIV-1 entry inhibitors that prevent gp120 binding to CD4.

  2005cited by this paper
• HIV vaccine design and the neutralizing antibody problem

  2004cited by this paper
• Envelope-Constrained Neutralization-Sensitive HIV-1 After Heterosexual Transmission

  2004cited by this paper
• Antibodies, viruses and vaccines

  2002cited by this paper
• Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy.

  2002cited by this paper
• Erratum: Emergence of autologous neutralization-resistant variants from preexisting human immunodeficiency virus (HIV) quasi species during virus rebound in HIV type 1-infected patients undergoing highly active antiretroviral therapy (Journal of Infectious Disease (2002) 185 (608-617))

  2002cited by this paper
• A Potent Human Immunodeficiency Virus Type 1 Protease Inhibitor, UIC-94003 (TMC-126), and Selection of a Novel (A28S) Mutation in the Protease Active Site

  2002cited by this paper
• Viral persistence: HIV's strategies of immune system evasion.

  2002cited by this paper
• Reconstitution of spontaneous neutralizing antibody response against autologous human immunodeficiency virus during highly active antiretroviral therapy.

  2002cited by this paper
• Protein modelling for all.

  1999cited by this paper
• JE-2147: a dipeptide protease inhibitor (PI) that potently inhibits multi-PI-resistant HIV-1.

  1999cited by this paper
• Structure of an HIV gp120 envelope glycoprotein in complex with the CD4 receptor and a neutralizing human antibody

  1998influential reference
• The antigenic structure of the HIV gp120 envelope glycoprotein

  1998cited by this paper
• Merck molecular force field. I. Basis, form, scope, parameterization, and performance of MMFF94

  1996cited by this paper
• A trimeric structural domain of the HIV-1 transmembrane glycoprotein

  1995cited by this paper
• Characterization of conserved human immunodeficiency virus type 1 gp120 neutralization epitopes exposed upon gp120-CD4 binding

  1993cited by this paper
• Steroid-receptor fusion of the human immunodeficiency virus type 1 Rev transactivator: mapping cryptic functions of the arginine-rich motif.

  1990cited by this paper
• A simple generalized equation for the analysis of multiple inhibitions of Michaelis-Menten kinetic systems.

  1977influential reference

• CD4 Mimic‐Neutralizing Antibody Conjugates Synthesized by Site‐Specific Modification Methods as HIV‐1 Entry Inhibitors

  2026cites this paper
• Antibody-Drug Conjugates Using CD4 Mimics and a Neutralizing Antibody as HIV-1 Entry Inhibitors.

  2025cites this paper
• CD4-mimetics sensitize HIV-infected cells to ADCC mediated by plasma from persons with early-stage HIV-1 infection

  2025cites this paper
• Hybrid Molecules of Small Molecular and Peptidic HIV Fusion Inhibitors

  2025cites this paper
• Development of Small-Molecule Anti-HIV-1 Agents Targeting HIV-1 Capsid Proteins.

  2024cites this paper
• In vivo evolution of env in SHIV-AD8EO-infected rhesus macaques after AAV-vectored delivery of eCD4-Ig

  2024cites this paper
• V3 tip determinants of susceptibility to inhibition by CD4-mimetic compounds in natural clade A human immunodeficiency virus (HIV-1) envelope glycoproteins

  2023cites this paper
• Indoline CD4-mimetic compounds mediate potent and broad HIV-1 inhibition and sensitization to antibody-dependent cellular cytotoxicity

  2023cites this paper
• Low-molecular-weight anti-HIV-1 agents targeting HIV-1 capsid proteins

  2023cites this paper
• Small-Molecule HIV Entry Inhibitors Targeting gp120 and gp41.

  2022cites this paper
• Exploratory studies on soluble small molecule CD4 mimics as HIV entry inhibitors.

  2022cites this paper
• Hybrids of small CD4 mimics and gp41-related peptides as dual-target HIV entry inhibitors.

  2022cites this paper
• Characterization of Human Immunodeficiency Virus (HIV-1) Envelope Glycoprotein Variants Selected for Resistance to a CD4-Mimetic Compound

  2022cites this paper
• The HIV Env Glycoprotein Conformational States on Cells and Viruses

  2022cites this paper
• Small-Molecule Anti-HIV-1 Agents Based on HIV-1 Capsid Proteins

  2021cites this paper
• Ultrafast topological data analysis reveals pandemic-scale dynamics of convergent evolution

  2021cites this paper
• Hybrids of Small-Molecule CD4 Mimics with Polyethylene Glycol Units as HIV Entry Inhibitors.

  2021cites this paper
• Common evolutionary features of the envelope glycoprotein of HIV-1 in patients belonging to a transmission chain

  2020cites this paper
• Potent leads based on CA-19L, an anti-HIV active HIV-1 capsid fragment.

  2020cites this paper
• Bivalent HIV-1 fusion inhibitors based on peptidomimetics.

  2020cites this paper
• Exploratory studies on CA-15L, an anti-HIV active HIV-1 capsid fragment.

  2020cites this paper
• CD4 occupancy triggers sequential pre-fusion conformational states of the HIV-1 envelope trimer with relevance for broadly neutralizing antibody activity

  2019cites this paper
• Discovery and Development of Anti-HIV Therapeutic Agents: Progress Towards Improved HIV Medication

  2019cites this paper
• In Silico Identification of Novel Aromatic Compounds as Potential HIV-1 Entry Inhibitors Mimicking Cellular Receptor CD4

  2019cites this paper
• Strain-Dependent Activation and Inhibition of Human Immunodeficiency Virus Entry by a Specific PF-68742 Stereoisomer

  2019cites this paper
• Soluble-type small-molecule CD4 mimics as HIV entry inhibitors.

  2019cites this paper
• Conjugated Compounds Involving Peptides

  2018cites this paper
• A CD4-mimetic compound enhances vaccine efficacy against stringent immunodeficiency virus challenge

  2018cites this paper
• Phenotypic properties of envelope glycoproteins of transmitted HIV-1 variants from patients belonging to transmission chains

  2018influential citation
• Flexibility of small molecular CD4 mimics as HIV entry inhibitors.

  2018cites this paper
• Isolation and structure determination of a new lasso peptide specialicin based on genome mining.

  2018cites this paper
• Driving HIV-1 into a Vulnerable Corner by Taking Advantage of Viral Adaptation and Evolution

  2017influential citation
• Computational identification of novel entry inhibitor scaffolds mimicking primary receptor CD4 of HIV-1 gp120

  2017cites this paper
• HIV-1 Entry and Fusion Inhibitors: Mechanisms and Resistance

  2017cites this paper
• Development of anti‐HIV peptides based on a viral capsid protein

  2017cites this paper
• Cross-Neutralization Activity of Single-Chain Variable Fragment (scFv) Derived from Anti-V3 Monoclonal Antibodies Mediated by Post-Attachment Binding.

  2016cites this paper
• Rôle de la conformation des glycoprotéines de l’enveloppe du VIH-1 dans la réponse cytotoxique cellulaire dépendante des anticorps et impact des protéines virales Nef et Vpu

  2016cites this paper
• Enhanced antibody-mediated neutralization of HIV-1 variants that are resistant to fusion inhibitors

  2016cites this paper
• Impact of the Maraviroc-Resistant Mutation M434I in the C4 Region of HIV-1 gp120 on Sensitivity to Antibody-Mediated Neutralization.

  2016cites this paper
• Activation and Inactivation of Primary Human Immunodeficiency Virus Envelope Glycoprotein Trimers by CD4-Mimetic Compounds

  2016cites this paper
• Small‐Molecule CD4 Mimics Containing Mono‐cyclohexyl Moieties as HIV Entry Inhibitors

  2016cites this paper
• Patterns of HIV/SIV Prevention and Control by Passive Antibody Immunization

  2016cites this paper
• Antibodies Elicited by Multiple Envelope Glycoprotein Immunogens in Primates Neutralize Primary Human Immunodeficiency Viruses (HIV-1) Sensitized by CD4-Mimetic Compounds

  2016cites this paper
• Multimerized HIV‐gp41‐derived peptides as fusion inhibitors and vaccines

  2016cites this paper
• A minimally cytotoxic CD4 mimic as an HIV entry inhibitor.

  2016cites this paper
• Passive transfer of neutralizing mAb KD-247 reduces plasma viral load in patients chronically infected with HIV-1

  2015cites this paper
• Structure-Based Design of a Small Molecule CD4-Antagonist with Broad Spectrum Anti-HIV-1 Activity.

  2015cites this paper
• Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41.

  2015cites this paper
• Incompatible Natures of the HIV-1 Envelope in Resistance to the CCR5 Antagonist Cenicriviroc and to Neutralizing Antibodies

  2015cites this paper
• Anti-HIV screening for cell-penetrating peptides using chloroquine and identification of anti-HIV peptides derived from matrix proteins.

  2015cites this paper
• Impact of maraviroc-resistant and low-CCR5-adapted mutations induced by in vitro passage on sensitivity to anti-envelope neutralizing antibodies.

  2014influential citation
• Binding Mode Characterization of NBD Series CD4-Mimetic HIV-1 Entry Inhibitors by X-Ray Structure and Resistance Study

  2014cites this paper
• Crystal Structures of HIV-1 gp120 Envelope Glycoprotein in Complex with NBD Analogues That Target the CD4-Binding Site

  2014cites this paper
• CD4-Mimetic Small Molecules Sensitize Human Immunodeficiency Virus to Vaccine-Elicited Antibodies

  2014cites this paper
• Inhibitors of human immunodeficiency virus type 1 (HIV-1) attachment. 12. Structure-activity relationships associated with 4-fluoro-6-azaindole derivatives leading to the identification of 1-(4-benzoylpiperazin-1-yl)-2-(4-fluoro-7-[1,2,3]triazol-1-yl-1h-pyrrolo[2,3-c]pyridin-3-yl)ethane-1,2-dione (B

  2013cites this paper
• Rational design of HIV-1 entry inhibitors.

  2013cites this paper
• Mechanisms of anti-retroviral drug resistance: implications for novel drug discovery and development.

  2013cites this paper
• Inhibitors of HIV-1 attachment. Part 10. The discovery and structure-activity relationships of 4-azaindole cores.

  2013cites this paper
• Conformational Epitope Consisting of the V3 and V4 Loops as a Target for Potent and Broad Neutralization of Simian Immunodeficiency Viruses

  2013cites this paper
• CD4 mimics as HIV entry inhibitors: lead optimization studies of the aromatic substituents.

  2013cites this paper
• Generation of a replication-competent simian-human immunodeficiency virus, the neutralization sensitivity of which can be enhanced in the presence of a small-molecule CD4 mimic.

  2013cites this paper
• A CD4 mimic as an HIV entry inhibitor: pharmacokinetics.

  2013cites this paper
• Impact of antiretroviral pressure on selection of primary human immunodeficiency virus type 1 envelope sequences in vitro.

  2013cites this paper
• Synergism between a CD4-mimic peptide and antibodies elicited by a constrained V3 peptide.

  2013influential citation
• Inhibitors of HIV-1 attachment. Part 11: the discovery and structure-activity relationships associated with 4,6-diazaindole cores.

  2013cites this paper
• Mechanisms of CCR5 Agonist/Antagonist Inhibition of HIV-1 Entry and In Vitro Selection of Virus Resistant to Maraviroc

  2013cites this paper
• MiniCD4 protein resistance mutations affect binding to the HIV-1 gp120 CD4 binding site and decrease entry efficiency

  2012influential citation
• Structural Dynamics of HIV-1 Envelope Gp120 Outer Domain with V3 Loop

  2012cites this paper
• Design, synthesis, and antiviral activity of entry inhibitors that target the CD4-binding site of HIV-1.

  2012cites this paper
• In vitro and In vivo Resistance to Human Immuno Deficiency Virus Type 1 Entry Inhibitors

  2012influential citation
• [Development of anti-HIV agents based on chemical biology].

  2012cites this paper
• Peptides presenting the binding site of human CD4 for the HIV-1 envelope glycoprotein gp120

  2012cites this paper
• Conjugation of cell-penetrating peptides leads to identification of anti-HIV peptides from matrix proteins.

  2012cites this paper
• Escape from Human Immunodeficiency Virus Type 1 (HIV-1) Entry Inhibitors

  2012influential citation
• Design, synthesis and biological evaluation of small molecule inhibitors of CD4-gp120 binding based on virtual screening.

  2011cites this paper
• The successes and failures of HIV drug discovery

  2011cites this paper
• Small molecular CD4 mimics as HIV entry inhibitors.

  2011cites this paper
• CD4 mimics targeting the HIV entry mechanism and their hybrid molecules with a CXCR4 antagonist.

  2010cites this paper